1 Introduction
==============

Tumours turn malignant in a Darwinian evolutionary process by accumulating genetic mutations, copy number alterations, changes in DNA methylation, gene expression and protein concentration. Such progression events arise in individual tumour cells, but their effect on the reproductive fitness of this cell depends on earlier events ([@btz513-B32]), which makes some chronological sequences of alterations more likely than others. These sequences and their driving dependencies are a priori unknown and inferring them from data is the goal of cancer progression models. These roughly fall into three classes: phylogenetic models, models of population dynamics and cross-sectional models ([@btz513-B7]; [@btz513-B35]). We focus on the latter.

While progression is a dynamic process, available genotype data are cross-sectional and combine static snapshots from different tumours at different stages of development. Nevertheless, assuming that the tumour genomes are observations from the same stochastic process, cancer progression models can infer dependencies between events from their co-occurrence patterns. The dependencies are then reported as a directed graph, where each node stands for an event whose probability depends in some way on the events connected to it by incoming edges ([Fig. 1](#btz513-F1){ref-type="fig"}).

![Overview of several types of cancer progression models. For models with deterministic dependencies (a-e) $\left. A\rightarrow B \right.$ denotes that A is necessary for B, and $A \dashv B$ denotes that A prevents B. For models with stochastic dependencies (f,g) $\left. A\rightarrow B \right.$ denotes that A makes B more likely, and $A \dashv B$ denotes that A makes B less likely. In (d-e) the arrows between groups of events denote that at least one of the events in the parent group is necessary for the events in the child group](btz513f1){#btz513-F1}

For example, one family of models \[reviewed by [@btz513-B21]\] approximate tumour progression by deterministic dependencies: An event has a non-zero probability if and only if all its parent events have occurred. These models were inspired by [@btz513-B17], who inferred that colorectal cancers progress along a chain of mutations in the genes *APC → K-RAS → TP53*. [@btz513-B15] formalized and extended this concept to Oncogenetic Trees, where a single event may be necessary for multiple successor events in parallel. [@btz513-B6] further generalized these to Conjunctive Bayesian Networks (CBN), where events may require multiple precursors, thus replacing trees by directed acyclic graphs.

In this paper, we relax three assumptions of this model family: Dependencies need not be deterministic. An event A can make an event B more likely without being absolutely necessary for it. In particular, events can occur with non-zero probability at all times and all event patterns are possible.A dependency graph need not be acyclic. Why should it? Clearly an event A cannot be necessary for B if B is also necessary for A. But it is certainly possible that A makes B more likely when it occurs first, and vice versa.Besides enabling dependencies, there are also inhibiting dependencies.

Although there is, to the best our knowledge, no method that addresses all three issues, there are methods that address one or two of them. Stochastic dependencies (1) have been previously proposed in [@btz513-B16]), [@btz513-B30]) and [@btz513-B33] for acyclic models. Moreover, stochasticity at the point of observation has been addressed by [@btz513-B19] who allow for mislabeled events, and in [@btz513-B5] and [@btz513-B31] who treat tumour data as a mixture from multiple stochastic processes. Network Aberration Models (NAM) by [@btz513-B23] have stochastic dependencies (1) and allow cycles in their dependency graph (2).

Inhibition (3) is at the centre of mutual exclusivity, which is a frequently observed phenomenon in cancer ([@btz513-B41]). Two events are considered mutually exclusive if they co-occur less frequently than expected by chance. There are at least two mechanisms that can cause this data pattern: (i) Synthetic lethality, where cells carrying two mutations A and B are no longer vital. (ii) The events disrupt the same molecular pathway such that whichever event occurs first conveys most of the selective advantage and decreases selective pressure for the others. Both mechanisms can be described by a double edge A $\vdash \dashv$ B (A inhibits B, and B inhibits A)

[@btz513-B19] proposed to model pathways within a progression model from biological prior knowledge. They extracted predefined sets of events from databases reflecting biological pathways which are considered affected if at least one of its constituent events has occurred. Tumour progression is then modelled on the level of pathways rather than events.

Alternatively pathways can be derived from data by detecting patterns of mutual exclusivity (Constantinescu *et al.*, 2015; [@btz513-B26]; [@btz513-B29]; [@btz513-B36]) or by a combination of knowledge and data ([@btz513-B11]; [@btz513-B24]), see ([@btz513-B38]) for a review. [@btz513-B34] pointed out that inferring pathways separately from their dependencies can lead to inconsistencies in the presence of noise. They presented the first algorithm that simultaneously groups events into pathways and arranges the pathways in a linear chain. PathTiMEx ([@btz513-B14]) generalizes this from linear chains to acyclic progression networks (CBN).

Building on both CBNs and NAMs, we propose Mutual Hazard Networks (MHN). MHNs do not group events into pathways but directly model the mechanisms behind mutual exclusivity. MHNs have cyclic dependency networks, in particular allowing for bidirectional and inhibiting edges.

MHN characterize events by a baseline rate and by multiplicative effects they exert on the rates of successive events. These effects can be greater or less than one, i.e. promoting or inhibiting. We provide formulas for the log-likelihood of MHN and its gradient, and an implementation that is computationally tractable for systems with up to 25 events on a standard workstation and for larger systems on an HPC infrastructure.

2 Materials and methods
=======================

2.1 Mutual Hazard Networks
--------------------------

We model tumour progression as a continuous time Markov process $\left\{ {X\left( t \right),t \geq 0} \right\}$ on all $2^{n}$ combinations of a predefined set of *n* events. Its state space is $S = \left\{ {0,1} \right\}^{n}$, where $X\left( t \right)_{i} = 1$ means that event *i* has occurred in the tumour by age *t*, while $X\left( t \right)_{i} = 0$ means that it has not.

We assume that every progression trajectory starts at a normal genome $X\left( 0 \right) = \left( 0,\ldots,0 \right)^{T}$, accumulates irreversible events one at a time, and ends at a fully aberrant genome $X\left( \infty \right) = \left( 1,\ldots,1 \right)^{T}$. Observed tumour genomes correspond to states at unknown intermediate ages $0 < t < \infty$ and typically hold both 0 and 1 entries.

Let $Q \in \mathbb{R}^{2^{n} \times 2^{n}}$ be the transition rate matrix of this process with respect to a basis of *S* in lexicographic order ([Fig. 2](#btz513-F2){ref-type="fig"}, left). An entry $$Q_{\mathbf{y},\mathbf{x}} = \lim\limits_{\Delta t\rightarrow 0}\frac{\Pr\left( X\left( t + \Delta t \right) = \mathbf{y} \middle| X\left( t \right) = \mathbf{x} \right)}{\Delta t},\quad\mathbf{y} \neq \mathbf{x}$$is the rate from state $\mathbf{x} \in S$ to state $\mathbf{y} \in S$, and diagonal elements are defined as $Q_{\mathbf{x},\mathbf{x}} = - \sum\limits_{\mathbf{y} \neq \mathbf{x}}Q_{\mathbf{y},\mathbf{x}}$ so that columns sum to zero. *Q* is lower triangular and has non-zero entries only for transitions between pairs of states $\mathbf{x} = \left( \ldots,x_{i - 1},0,x_{i + 1},\ldots \right)^{T}$ and $\mathbf{y} = \mathbf{x}_{+ i}: = \left( \ldots,x_{i - 1},1,x_{i + 1},\ldots \right)^{T}$ that differ in a single entry *i*.

![(Left) Transition rate matrix *Q* for the Markov process *X* with *n *=* *4, where $\cdot$ is a zero entry and $\bullet$ is a non-zero entry. The states are depicted as squares with four compartments as shown below. A white compartment denotes 0 and a black compartment denotes 1. The matrix is lower triangular because events are irreversible, and sparse because events accumulate one at a time. (Right) Parameterization $Q_{\Theta}$ of the Markov process by a Mutual Hazard Network](btz513f2){#btz513-F2}

Our aim is to learn for each event *i* how its rate $Q_{\mathbf{x}_{+ i},\mathbf{x}}$ depends on already present events in **x** as a function $\left. f_{i}:\left\{ {0,1} \right\}^{n}\rightarrow\mathbb{R} \right.$. A common choice in time-to-event analysis is the proportional hazards model ([@btz513-B13]) which assumes that binary predictors have independent and multiplicative effects on the rate of the event. We therefore specify the Markov process by a system of *n* functions $$Q_{\mathbf{x}_{+ i},\mathbf{x}} = f_{i}\left( \mathbf{x} \right) = \text{exp}\,\left( {\theta_{\mathit{ii}} + \sum\limits_{j = 1}^{n}\theta_{\mathit{ij}}x_{j}} \right) = \Theta_{\mathit{ii}}\prod\limits_{x_{j} = 1}\Theta_{\mathit{ij}}\,$$and collect their parameters in a matrix $\left( \Theta_{\mathit{ij}} \right): = \left( e^{\theta_{\mathit{ij}}} \right) \in \mathbb{R}^{n \times n}$. We call Θ a *Mutual Hazard Network (MHN)*, where the baseline hazard Θ~*ii*~ is the rate of the event *i* before any other events are present and the hazard ratio Θ~*ij*~ is the multiplicative effect of event *j* on the rate of event *i* ([Fig. 2](#btz513-F2){ref-type="fig"}, right). Note that while the baseline hazard in [@btz513-B13] is generally a function of time, here it must be constant so that our model constitutes a Markov process.

2.2 Parameter estimation
------------------------

A dataset $\mathcal{D}$ of tumours defines an empirical probability distribution on *S*. It can be represented by a vector $\mathbf{p}_{\mathcal{D}}$ of size $2^{n}$, where an entry $\left( \mathbf{p}_{\mathcal{D}} \right)_{\mathbf{x}}$ is the relative frequency of observed tumours with state **x** in $\mathcal{D}$.

At *t *=* *0 tumours are free of any events, so the Markov process *X* starts with the initial distribution $\mathbf{p}_{\varnothing}: = \left( 100\%,0\%,\ldots,0\% \right)^{T}$, which then evolves according to the parameterized rate matrix $Q_{\Theta}$. If all tumours had been observed at a common age *t*, $\mathbf{p}_{\mathcal{D}}$ could be modelled as a sample from the transient distribution $$e^{tQ_{\Theta}}\mathbf{p}_{\varnothing}.$$

Since the tumour age is usually unknown, we follow [@btz513-B18] and consider *t* to be an exponential random variable with mean 1. Marginalizing over *t* yields $$\mathbf{p}_{\Theta} = {\int_{0}^{\infty}d}te^{- t}e^{tQ_{\Theta}}\mathbf{p}_{\varnothing} = {\underset{= :R_{\Theta}}{\underset{︸}{\left\lbrack I-Q_{\Theta} \right\rbrack}}}^{- 1}\mathbf{p}_{\varnothing},$$and the marginal log-likelihood score of Θ given $\mathcal{D}$ is $$\mathcal{S}_{\mathcal{D}}\left( \Theta \right) = \mathbf{p}_{\mathcal{D}}^{T}\,\text{log}\,\mathbf{p}_{\Theta} = \mathbf{p}_{\mathcal{D}}^{T}\,\text{log}\left( R_{\Theta}^{- 1}\mathbf{p}_{\varnothing} \right),$$where the logarithm of a vector is taken component-wise.

When optimizing $\mathcal{S}_{\mathcal{D}}$ with respect to Θ we further add an L1 penalty in order to control for model complexity and to avoid overfitting. This promotes sparsity of the networks, such that many events do not interact and off-diagonal entries Θ~*ij*~ are exactly 1: $$\left. \mathcal{S}_{\mathcal{D}}\left( \Theta \right) - \lambda\sum\limits_{i \neq j} \middle| \,\text{log}\,\Theta_{\mathit{ij}} \middle| , \right.$$where *λ* is a tuning parameter. We will optimize this expression using the Orthant-Wise Limited-Memory Quasi-Newton algorithm ([@btz513-B3]). This general-purpose optimizer handles the non-differentiable regularization term by approximating the objective at each iteration with a quadratic function that is valid within an orthant of the current set of (logarithmic) parameters. It requires only a closed form for the derivatives $\partial\mathcal{S}_{\mathcal{D}}/\partial\Theta_{\mathit{ij}}$ with respect to each parameter.

From the chain rule of matrix calculus we have $$\begin{array}{l}
\begin{array}{ll}
\frac{\partial\mathcal{S}_{\mathcal{D}}}{\partial\Theta_{\mathit{ij}}} & {= \frac{\partial\mathcal{S}_{\mathcal{D}}}{\partial R_{\Theta}^{- 1}} \cdot \frac{\partial R_{\Theta}^{- 1}}{\partial\Theta_{\mathit{ij}}}} \\
\end{array} \\
\begin{array}{ll}
 & {= \frac{\mathbf{p}_{\mathcal{D}}}{\mathbf{p}_{\Theta}}\mathbf{p}_{\varnothing}^{T} \cdot \left( {- R_{\Theta}^{- 1}\frac{\partial R_{\Theta}}{\partial\Theta_{\mathit{ij}}}R_{\Theta}^{- 1}} \right)} \\
\end{array} \\
\begin{array}{ll}
 & {= - \left( \frac{\mathbf{p}_{\mathcal{D}}}{\mathbf{p}_{\Theta}} \right)^{T}R_{\Theta}^{- 1}\frac{\partial R_{\Theta}}{\partial\Theta_{\mathit{ij}}}R_{\Theta}^{- 1}\mathbf{p}_{\varnothing},} \\
\end{array} \\
\end{array}$$where $\cdot$ is the Frobenius product and the ratio $\mathbf{p}_{\mathcal{D}}/\mathbf{p}_{\Theta}$ is computed component-wise.

In general this optimization converges to one local optimum out of possibly several depending on the starting point. In this paper we always report the optimum reached from an independence model, where the baseline hazard Θ~*ii*~ of each event was set to its empirical odds and the hazard ratios were set to exactly 1.

2.3 Efficient implementation
----------------------------

To compute the score in [equation (5)](#E5){ref-type="disp-formula"} and its gradient in [equation (7)](#E7){ref-type="disp-formula"} we must solve the exponentially sized linear systems $\left\lbrack {I - Q_{\Theta}} \right\rbrack^{- 1}\mathbf{p}_{\varnothing}$ and $\left( {\mathbf{p}_{\mathcal{D}}/\mathbf{p}_{\Theta}} \right)^{T}\left\lbrack {I - Q_{\Theta}} \right\rbrack^{- 1}$. To this end, we employ the (left) Kronecker product which is defined for matrices $A \in \mathbb{R}^{k \times l}$ and $B \in \mathbb{R}^{p \times q}$ as the block matrix $$A \otimes B = \begin{bmatrix}
{b_{11}A} & \cdots & {b_{1l}A} \\
 \vdots & \ddots & \vdots \\
{b_{k1}A} & \cdots & {b_{\mathit{kl}}A} \\
\end{bmatrix} \in \mathbb{R}^{\mathit{kp} \times \mathit{lq}}.$$

We follow the literature on structured analysis of large Markov chains ([@btz513-B2]; [@btz513-B8]) and write the transition rate matrix $Q_{\Theta}$ as a sum of *n* such Kronecker products, $$Q_{\Theta} = \sum\limits_{i = 1}^{n}\left\lbrack {\underset{j < i}{\otimes}\begin{pmatrix}
1 & 0 \\
0 & \Theta_{\mathit{ij}} \\
\end{pmatrix} \otimes \begin{pmatrix}
{- \Theta_{\mathit{ii}}} & 0 \\
{~\Theta_{\mathit{ii}}} & 0 \\
\end{pmatrix} \otimes \underset{j > i}{\otimes}\begin{pmatrix}
1 & 0 \\
0 & \Theta_{\mathit{ij}} \\
\end{pmatrix}} \right\rbrack.$$

Here, the *i*th term in the sum is a sparse $2^{n} \times 2^{n}$ matrix consisting of all transitions that introduce event *i* to the genome. It corresponds to a single subdiagonal of $Q_{\Theta}$, together with a negative copy on the diagonal to ensure that columns sum to zero (see Supplementary Section S2). The benefit of this compact representation is that matrix-vector products can be computed in $\mathcal{O}\left( n2^{n - 1} \right)$ rather than $\mathcal{O}\left( 2^{2n} \right)$ without holding the matrix explicitly in memory ([@btz513-B9]). We split $R_{\Theta} = I - Q_{\Theta}$ into a diagonal and strictly lower triangular part, $$R_{\Theta} = D + L = D\left( I + D^{- 1}L \right),$$and use the nilpotency of $D^{- 1}L$ to compute $$\begin{matrix}
{R_{\Theta}^{- 1}\mathbf{p}_{\varnothing} = \left( I + D^{- 1}L \right)^{- 1}D^{- 1}\mathbf{p}_{\varnothing}} \\
{= \left( {\sum\limits_{k = 0}^{n - 1}\left( - D^{- 1}L \right)^{k}} \right)D^{- 1}\mathbf{p}_{\varnothing}.} \\
\end{matrix}$$

3 Results
=========

3.1 Simulations
---------------

We tested in simulation experiments how well an MHN of a given size can learn a probability distribution on *S* when trained on a given amount of data. We ran 50 simulations for each of several sample sizes $\left| \mathcal{D} \middle| \in \left\{ 100,250,500,1000 \right\} \right.$ and number of events $n \in \left\{ 10,15,20 \right\}$.

In each simulation run, we chose a ground truth model Θ with *n* possible events. A random half of its off-diagonal entries were set to 1 (no dependency) and the remaining off-diagonal entries were drawn from a standard log-normal distribution. For the diagonal entries we chose the largest *n* out of 20 rates drawn from a log-normal distribution with mean $\mu = - 2$ and variance $\sigma^{2} = 1$. This was done to mimick the event frequencies observed in the biological datasets in Section 3.2 and yielded on average 2.7, 3.5 and 3.9 realized events in tumours with $n \in \left\{ 10,15,20 \right\}$ possible events.

We then generated a dataset of size $\left| \mathcal{D} \right|$ from each model and trained on it another model $\hat{\Theta}$ by optimizing expression (6). We chose a common regularization parameter for all 50 simulation runs, which we found to be roughly $\left. \lambda = 1/ \middle| \mathcal{D} \right|$ through validation on separate datasets of each sample size. We then assessed the reconstructed model $\hat{\Theta}$ by the Kullback-Leibler (KL) divergence from its probability distribution to the distribution of the true model Θ, $$D_{\text{KL}}\left( \mathbf{p}_{\Theta} \right\|\left. \mathbf{p}_{\hat{\Theta}} \right) = \mathbf{p}_{\Theta}^{T}\,\text{log}\,\mathbf{p}_{\Theta} - \mathbf{p}_{\Theta}^{T}\,\text{log}\,\mathbf{p}_{\hat{\Theta}}.$$

The median KL divergence, as well as its variance over the 50 simulation runs, improved with larger training datasets and reached almost zero ([Fig. 3](#btz513-F3){ref-type="fig"}).

![KL divergence from estimated MHNs to ground truth MHNs over 50 simulations for the shown sample sizes and number of events](btz513f3){#btz513-F3}

Next, we simulated datasets of size $\left| \mathcal{D} \middle| = 500 \right.$ from random MHNs and CBNs as ground truth models with *n *=* *8 events. We added noise by flipping each event independently with probability *ϵ*, trained MHNs and CBNs on both datasets and evaluated how well the estimated models fit the distribution of the ground truth models. ([Fig. 4](#btz513-F4){ref-type="fig"}) shows the average KL divergence over 5 simulation runs for each noise level $\epsilon \in \left\{ 1\%,5\%,10\%,15\%,20\% \right\}$. For CBNs as ground truth we found that CBNs outperformed MHNs when noise was below 10%, while MHNs performed better than CBNs at higher levels of noise. For MHNs as ground truth we found that MHNs performed better than CBNs at all levels of noise.

![Average KL divergence from estimated MHNs/CBNs to ground truth MHNs/CBNs over 5 simulations for each of the shown noise levels](btz513f4){#btz513-F4}

Lastly, we tested the performance of our implementation. The runtime of a single gradient step for random and dense Θ was about 1 min for *n *=* *20 on a standard workstation and scaled exponentially with *n* as expected (see [Supplementary Section S2](#sup1){ref-type="supplementary-material"} for details).

3.2 Application to cancer progression data
------------------------------------------

### *3.2.1* Comparison to conjunctive Bayesian Networks

We tested our method and first compared it to Conjunctive Bayesian Networks (CBN) on three cancer datasets that were previously used by [@btz513-B18]. They were obtained from the Progenetix molecular-cytogenetic database ([@btz513-B4]) and consist of 817 breast cancers, 570 colorectal cancers, and 251 renal cell carcinomas. The cancers are characterized by 10, 11 and 12 recurrent copy number alterations, respectively, which were detected by comparative genomic hybridization (CGH). On average 3.3, 3.5 and 2.6 of these possible events were observed in individual tumours within each dataset.

We trained MHNs on all three datasets (see [Supplementary Section S3](#sup1){ref-type="supplementary-material"}) and compared them to the CBNs given in [@btz513-B18] which provide log-likelihood scores in-sample. The in-sample scores of MHNs are not directly comparable because MHNs have more degrees of freedom than CBNs. Therefore we additionally provide the average log-likelihood scores of MHNs in 5-fold cross-validation and the Akaike Information Criterion ([@btz513-B1]) (AIC) for both models. MHN compared favourably on all three datasets ([Table 1](#btz513-T1){ref-type="table"}).

###### 

MHNs compare favourably to CBNs on three datasets in terms of the log-likelihood scores per tumour, averaged over 5 folds in cross-validation

                         Cross-validated   In-sample   AIC                  
  ---------------------- ----------------- ----------- ------- ------------ ------
  Breast cancer          −5.63             −5.73       −5.54    $\geq$9373  9152
  Colorectal cancer      −5.64             −5.79       −5.41    $\geq$6612  6288
  Renal cell carcinoma   −5.02             −5.13       −4.81    $\geq$2587  2559

*Note*: They also compare favourably in terms of the AIC which penalizes the number of parameters in a model and is weighted by the sample size. While MHNs have *n*^2^ continuous parameters, CBNs have *n* continuous parameters and a discrete graph structure that is hard to quantify in terms of degrees of freedom, hence we ignore the latter and bound the AIC of CBNs from below.

### *3.2.2* Comparison to pathTiMEx

Next, we compared MHN to pathTiMEx on a glioblastoma dataset from The Cancer Genome Atlas ([@btz513-B10]) which was previously used in [@btz513-B14] (see [Fig. 5](#btz513-F5){ref-type="fig"}). The data consist of $\left| \mathcal{D} \middle| = 261 \right.$ tumours characterized by 486 point mutations (M), amplifications (A), or deletions (D). We focus on *n *=* *20 of these events which were pre-selected by pathTiMEx using the TiMEx algorithm ([@btz513-B12]). On average 3.3 of these possible events were observed in individual tumours.

![(**A**) Glioblastoma dataset from TCGA, where rows show events sorted by frequency and columns show tumours sorted lexicographically. The purple stripes highlight tumours which have IDH1(M) but lack TP53(M). (**B**) PathTiMEx model inferred in [@btz513-B14]. It simultaneously divides the dataset into pathways, i.e. into mutually exclusive groups of events and learns a CBN of these pathways. The CBN considers a pathway altered if at least one of its constituent events has occurred. A pathway alteration fixates at the rate given in the upper right-hand corner once all its parent pathways in the CBN have been altered. (**C**) Mutual Hazard Network, where nodes show the base rates Θ~*ii*~ and edges show the multiplicative interactions Θ~*ij*~. Similarities to pathTiMEx are highlighted in colour and roughly correspond to the signaling pathways Rb, p53 and PI(3)K (red, blue and green). (**D**) Highlighted data interpreted differently by the models. While both models explain the anti-correlation between *CDKN2A(D)* and *CDK4(A)* by mutual inhibition, pathTiMEx treats these as a group and infers a positive effect of any of these events on *MDM2(A)* from the correlation between *CDK4(A)* and *MDM2(A)*. MHN reports only a positive effect of *MDM2(A)* on *CDK4(A)* and in fact infers inhibition between *CDKN2A(D)* and *MDM2(A)* from their anti-correlation in the data](btz513f5){#btz513-F5}

We trained MHN as above for 100 iterations, which achieved a log-likelihood score of -7.70 in-sample and a score of -7.97 in 5-fold cross-validation. While pathTiMEx does not yield a directly comparable log-likelihood score, it quantifies discrepancies between model and data by considering the data to be corrupted by noise, each event in a tumour being independently flipped with probability *ε*. PathTiMEx estimated this noise parameter as $\hat{\varepsilon} = 20\%$, from which we gauge an upper bound on its log-likelihood score as follows: even a hypothetical model that learns the data distribution $\mathbf{p}_{\mathcal{D}}$ perfectly but assumes a level of noise $$\mathbf{p}_{\hat{\varepsilon}} = \otimes_{i = 1}^{n}\begin{pmatrix}
{1 - \hat{\varepsilon}} & \hat{\varepsilon} \\
\hat{\varepsilon} & {1 - \hat{\varepsilon}} \\
\end{pmatrix}\mathbf{p}_{\mathcal{D}}$$achieves only a score of $\mathbf{p}_{\mathcal{D}}^{T}\,\text{log}\,\mathbf{p}_{\hat{\varepsilon}} = - 8.50$ in-sample, which is less than the cross-validated score of MHN.

Nevertheless MHN largely agreed with pathTiMEx on the inhibitions implied by the three most mutually exclusive groups of events, which broadly correspond to the signaling pathways Rb, p53 and PI(3)K (red, blue and green in [Fig. 5](#btz513-F5){ref-type="fig"}) and are well known to be affected in glioblastoma ([@btz513-B28]).

The RB1 signaling pathway (red) regulates cell cycle progression and involves the genes *CDKN2A*, *CDK4* and *RB1*. *CDKN2A* codes for the tumour suppressor protein p16^INK4a^ which binds to CDK4 and prevents it from phosphorylizing RB1, thereby blocking cell cycle transition from G1 to S-phase. This function can be disrupted by deletion of *CDKN2A* or *RB1*, or by amplification of *CDK4*. MHN and pathTiMEx both report a corresponding inhibition between the events *CDKN2A(D)* and *CDK4(A)*, while MHN additionally reports inhibition between *CDKN2A(D)* and *RB1(D)*.

The p53 signaling pathway (blue) induces apoptosis in response to stress signals and involves the genes *TP53*, *MDM2*, *MDM4* and *CDKN2A*. *TP53* codes for the tumour suppressor protein p53 which is antagonized by MDM2 and MDM4 in a non-redundant manner ([@btz513-B37]). PathTiMEx identifies the events *TP53(M)*, *MDM2(A)*, *MDM4(A)* as mutually exclusive ways to evade apoptosis, while MHN reports inhibition only between *TP53(M)* and each of *MDM2(A)* and *MDM4(A)* separately. This may reflect non-diminishing returns due to their complementary roles in the pathway.

The gene *CDKN2A* is, in addition to its role in the RB1 pathway, also involved in the p53 pathway by coding for the protein p14^ARF^ in an alternate reading frame. p14^ARF^ physiologically inhibits MDM2, which suggests that a deletion of *CDKN2A* may be functionally similar to an amplification of *MDM2*. While MHN reports a corresponding inhibition between *CDKN2A(D)* and *MDM2(A)*, pathTiMEx cannot because this would lead to an overlap of pathways.

To the contrary, pathTiMEx implies that *CDKN2A(D)* promotes *MDM2(A)* despite their anti-correlation in the data ([Fig. 6D](#btz513-F6){ref-type="fig"}). We argue that this is an artifact driven by the assumption that all events in a group are interchangeable, and by the need to group *CDKN2A(D)* with *CDK4(A)* which is in turn highly correlated with *MDM2(A)*.

![Most likely chronological order of events for all 261 tumours in the glioblastoma dataset. Each of the 193 distinct tumour states corresponds to a terminal node in the tree or an internal node with a black outline and contains all events indicated by the symbols along the trajectory from the starting state (white circle in the centre). The order of events and the unobserved intermediate tumour states (internal nodes without a black outline) were imputed from the estimated transition rate matrix $Q_{\hat{\Theta}}$. To this end we used the uniformization method ([@btz513-B20]) to construct the time-discretized transition probability matrix $(I + Q_{\hat{\Theta}}/\gamma)$, where *γ* is the greatest absolute diagonal entry of $Q_{\hat{\Theta}}$. The most likely trajectories from the starting state to each observed tumour state were then computed using a single-source shortest path algorithm, where each transition was weighted by the negated logarithm of its probability](btz513f6){#btz513-F6}

The PI(3)K pathway (green) regulates cell proliferation and involves the genes *PTEN*, *PIK3CA*, *EGFR*, *PDGFRA*. While *IDH1* is not a canonical member of the PI(3)K pathway, MHN reports an inhibition between *IDH1(M)* and *PTEN(M)* and pathTiMEx groups *IDH1(M)* together with *PTEN(M)*, *PTEN(D)* and *PIK3CA(M)*. Notably, MHN inferred that the rare event *IDH1(M)* promotes the more common event *TP53(M)*. This is further illustrated in [Figure 6](#btz513-F6){ref-type="fig"} which shows the most likely chronological order of events for all 261 tumours. Each of their 193 distinct states is represented by a path that starts at the root node and terminates at either a leaf node or an internal node with a black outline. As can be seen in the lower left, all tumours that contain *IDH1(M)* are located on a common branch and thus share an early mutation history initiated by *IDH1(M)*. This interpretation is in line with the fact that *IDH1(M)* is considered a defining attribute of the Proneural subtype of gliobastoma which is clinically distinct and also associated with *TP53(M)* ([@btz513-B39]). It is further supported by independent data from consecutive biopsies of gliomas where *IDH1(M)* in fact preceded *TP53(M)* ([@btz513-B40]).

4 Discussion
============

We presented Mutual Hazard Networks, a new framework for modelling tumour progression from cross-sectional observations. MHN are an extension of Conjunctive Bayesian Networks ([@btz513-B6]): The multiplicative dependencies between rates \[[Equation (2)](#E2){ref-type="disp-formula"}\] approximate the conjunctive dependencies of CBNs in the limit of a vanishing baseline hazard (see [Supplementary Section S1](#sup1){ref-type="supplementary-material"}). MHN are also an extension of Network Aberration Models ([@btz513-B23]): NAM also use multiplicative dependencies of rates but restrict hazard ratios to be greater than one, which cannot generate patterns of mutual exclusivity. Moreover, MHN further develop the idea of [@btz513-B34] and [@btz513-B14] that grouping events into 'pathways' of mutual exclusive events cannot be done independently from dependencies between pathways. In fact, MHN give up the concept of grouping events entirely. It is not needed anymore, because patterns of mutually exclusive events can be naturally formed by pairwise bidirectional inhibitions or longer inhibiting cycles \[such as between *TP53(M)*, *MDM2(A)* and *CDKN2A(D)*\], both allowing for overlapping pathways. Such overlap exists. The screening approach of [@btz513-B27] finds overlapping gene sets forming patterns of mutual exclusivity, nicely reflecting the fact that several cancer genes participate in multiple pathways ([@btz513-B28]). However, this approach does not yet embed overlapping pathways into progression models while MHNs do just this.

Still, MHN shares some limitations with earlier models. [@btz513-B25] have shown that back mutations, which MHNs cannot account for, do occur in tumour progression, although not frequently. Our proposed implementation of the MHN learning algorithm has a space and time complexity that is exponential in the number of events *n*, which compares similarly to [@btz513-B23] and trails ([@btz513-B31]). Therefore events have to be pre-selected by recurrency or more sophisticated approaches ([@btz513-B22]). In practice, we saw limits at *n *=* *25 on a standard workstation. Modern cancer datasets report hundreds of recurrent mutations, and the question arises whether MHN can deal with them. In fact we believe that MHN is competitive with other algorithms also for these large datasets, because interactions between low-frequency events cannot be resolved reliably at all. For example, in the glioblastoma dataset, the rare events *OBSCN(M), CNTNAP2(M), LRP2(M), TP53(D)* and *PAOX(M)* remained unconnected to the rest of the network. In other words, the evidence for possible interactions was so low that it could not compensate for the L1-costs of an additional edge. These are limitations in the data itself and not in computation times.

An interesting feature of MHN are the spontaneous occurrence/fixation rates Θ~*ii*~. The event pair *IDH1(M)* and *TP53(M)* was instructive for understanding their role. *IDH1* mutations were infrequent in the glioblastomas compared to *TP53* mutations. Moreover, 10 out of 14 *IDH1(M)* positive glioblastoma also showed a *TP53* mutation. We see at least two alternative explanations for this noisy subset pattern: (1) *TP53* mutations are needed for *IDH1* mutations to occur. (2) *TP53(M)* has a much higher spontaneous rate than *IDH1(M)* explaining that it is more frequent, and moreover, an *IDH1* mutation strongly increases the rate of a *TP53* mutation, explaining why so many *IDH1(M)* positive glioblastoma were also positive for *TP53(M)*. While both scenarios explain the noisy subset pattern, they disagree with respect to the chronological order of events. In (1) the *TP53* mutation precedes the *IDH1* mutation, while in (2) the events occur in reverse order. MHN decided for explanation (2) and is endorsed by independent data from consecutive biopsies ([@btz513-B40]). Where in the training data was the evidence in favour of (2) over (1)? If *TP53(M)* were necessary for *IDH1(M)*, we would expect *IDH1(M)* to have a very small spontaneous rate in the absence of *TP53(M)* and hence to occur later than other events, if at all. Yet, of the four cases that were *IDH1(M)* positive and *TP53(M)* negative, all of them had at most one mutation in addition to *IDH1(M)* ([Fig. 5A](#btz513-F5){ref-type="fig"}, purple), which is in line with (2) but not with (1).

In summary, we introduced a new, very flexible framework for tumour progression modelling that naturally accounts for cyclic interactions between events.
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